Evidence map›Paper›PMID 36343495›Full record

ReviewEpidemics2022

Considering equity in priority setting using transmission models: Recommendations and data needs.

M Quaife, G F Medley, M Jit, T Drake, M Asaria, P van Baal, R Baltussen, L Bollinger, F Bozzani, O Brady and 23 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Epidemics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 14 institutions in 3 countries.

M QuaifeDepartment of Global Health and Development, London School of Hygiene and Tropical Medicine, UK; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, UK.
G F MedleyDepartment of Global Health and Development, London School of Hygiene and Tropical Medicine, UK.
M JitDepartment of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, UK.
T DrakeCenter for Global Development in Europe (CGD Europe), UK.
M AsariaLSE Health, London School of Economics, UK.
P van BaalErasmus School of Health Policy & Management, Erasmus University Rotterdam, the Netherlands.
R BaltussenNijmegen International Center for Health Systems Research and Education, Radboudmc, the Netherlands.
L BollingerEconomics and Costing, Avenir Health, USA.
F BozzaniDepartment of Global Health and Development, London School of Hygiene and Tropical Medicine, UK.
O BradyDepartment of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, UK.
H BroekhuizenCentre for Space, Place, and Society, Wageningen University and Research, Netherlands.
K ChalkidouInternational Decision Support Initiative, Imperial College London, UK.
Y-L ChiInternational Decision Support Initiative, Imperial College London, UK.
D W DowdyDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, USA.
S GriffinCentre for Health Economics, University of York, UK.
H Haghparast-BidgoliInstitute for Global Health, Centre for Global Health Economics, University College London, UK.
T HallettDepartment of Infectious Disease Epidemiology, Imperial College London, UK.
K HauckDepartment of Infectious Disease Epidemiology, Imperial College London, UK.
T D HollingsworthBig Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, UK.
C F McQuaidDepartment of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, UK.
N A MenziesDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, USA.
M W MerrittJohns Hopkins Berman Institute of Bioethics and Department of International Health, Johns Hopkins Bloomberg School of Public Health, United States.
A MirelmanCentre for Health Economics, University of York, UK.
A MortonDepartment of Management Science, University of Strathclyde, UK.
F J RuizInternational Decision Support Initiative, Imperial College London, UK.
M SiapkaDepartment of Global Health and Development, London School of Hygiene and Tropical Medicine, UK; Impact Elipsis, Greece.
J SkordisInstitute for Global Health, Centre for Global Health Economics, University College London, UK.
F TediosiSwiss Tropical and Public Health Institute and Universität Basel, Switzerland.
P WalkerDepartment of Infectious Disease Epidemiology, Imperial College London, UK.
R G WhiteDepartment of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, UK.
P WinskillDepartment of Infectious Disease Epidemiology, Imperial College London, UK.
A VassallDepartment of Global Health and Development, London School of Hygiene and Tropical Medicine, UK. Electronic address: Anna.Vassall@lshtm.ac.uk.
G B GomezDepartment of Global Health and Development, London School of Hygiene and Tropical Medicine, UK.
London School of Hygiene & Tropical Medicine · GBImperial College London · GBUniversity College London · GBUniversity of York · GBAvenir Health · USErasmus University Rotterdam · NLHarvard Global Health Institute · USHealth Data Research UK · GBJohns Hopkins Berman Institute of Bioethics · USJohns Hopkins University · USLondon School of Economics and Political Science · GBRadboud University Nijmegen · NLUniversity of Strathclyde · GBWageningen University & Research · NL

Funding

Medical Research Council MR/R015600/1
6 · The paper itself

Abstract

objectivesDisease transmission models are used in impact assessment and economic evaluations of infectious disease prevention and treatment strategies, prominently so in the COVID-19 response. These models rarely consider dimensions of equity relating to the differential health burden between individuals and groups. We describe concepts and approaches which are useful when considering equity in the priority setting process, and outline the technical choices concerning model structure, outputs, and data requirements needed to use transmission models in analyses of health equity.

methodsWe reviewed the literature on equity concepts and approaches to their application in economic evaluation and undertook a technical consultation on how equity can be incorporated in priority setting for infectious disease control. The technical consultation brought together health economists with an interest in equity-informative economic evaluation, ethicists specialising in public health, mathematical modellers from various disease backgrounds, and representatives of global health funding and technical assistance organisations, to formulate key areas of consensus and recommendations.

resultsWe provide a series of recommendations for applying the Reference Case for Economic Evaluation in Global Health to infectious disease interventions, comprising guidance on 1) the specification of equity concepts; 2) choice of evaluation framework; 3) model structure; and 4) data needs. We present available conceptual and analytical choices, for example how correlation between different equity- and disease-relevant strata should be considered dependent on available data, and outline how assumptions and data limitations can be reported transparently by noting key factors for consideration.

conclusionsCurrent developments in economic evaluations in global health provide a wide range of methodologies to incorporate equity into economic evaluations. Those employing infectious disease models need to use these frameworks more in priority setting to accurately represent health inequities. We provide guidance on the technical approaches to support this goal and ultimately, to achieve more equitable health policies.

Indexed as

COVID-19Cost-Benefit AnalysisHealth PolicyHumansPublic HealthCost-effectiveness analysisEquityHealth economicsPrioritySettingTransmission modelling

Identifiers

PMID36343495
PMCPMC9623400
OpenAlexW4307761452

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.